Geron Corp (GERN): Total Assets
$570.54M
As of 2025-12-31
$519.01M
As of 2026-06-30
+44.1%
3-year compound annual growth
+16.1%
5-year compound annual growth
+14.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $570.54M | -3.9% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $593.78M | +50.7% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $394.08M | +106.8% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $190.57M | -15.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $226.03M | -16.5% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $270.73M | +63.6% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $165.52M | -10.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $185.28M | +68.0% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $110.31M | -15.3% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $130.25M | -12.4% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $148.76M | -13.8% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $172.51M | +156.2% | 2016-03-10, Balance as of period end |
| 2013-12-31 | $67.34M | -32.5% | 2015-03-11, Balance as of period end |
| 2012-12-31 | $99.80M | -37.6% | 2014-03-17, Balance as of period end |
| 2011-12-31 | $160.05M | -31.5% | 2013-03-15, Balance as of period end |
| 2010-12-31 | $233.58M | n/a | 2012-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | $570.54M | -3.9% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $552.60M | +13.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $594.82M | +10.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $598.73M | +20.3% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $605.19M | +1.9% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $533.43M | +18.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗